Eli Lilly to invest $3 billion in China over next decade

Core Viewpoint - Eli Lilly plans to invest $3 billion over the next decade to expand supply chain capacity in China and build production capacity for type-2 diabetes and obesity treatment orforglipron [1] Group 1: Investment Plans - The company is committing $3 billion for the expansion of its supply chain in China [1] - The investment will focus on increasing production capacity specifically for orforglipron, a treatment for type-2 diabetes and obesity [1] Group 2: Strategic Importance - This move highlights the company's strategy to enhance its operational capabilities in a key market [1] - The investment reflects a growing emphasis on addressing diabetes and obesity, which are significant health concerns globally [1]